Cuu Long Pharmaceutical Joint Stock Company

HOSE:DCL Stock Report

Market Cap: ₫2.0t

Cuu Long Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Cuu Long Pharmaceutical's earnings have been declining at an average annual rate of -0.4%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 12.9% per year. Cuu Long Pharmaceutical's return on equity is 4.3%, and it has net margins of 5.4%.

Key information

-0.4%

Earnings growth rate

-6.7%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate12.9%
Return on equity4.3%
Net Margin5.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cuu Long Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HOSE:DCL Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,185,59363,490148,1320
30 Jun 241,209,31962,651147,2070
31 Mar 241,185,10669,269134,0170
31 Dec 231,143,94661,717139,1880
30 Sep 231,099,85975,588134,4590
30 Jun 231,084,926104,295137,1940
31 Mar 231,035,081112,243152,3130
31 Dec 221,015,686108,641153,8150
30 Sep 22865,50190,616141,1500
30 Jun 22770,61177,850131,5220
31 Mar 22750,43484,405123,7330
31 Dec 21703,63483,961123,3710
30 Sep 21711,83381,435125,3840
30 Jun 21698,73280,446132,2250
31 Mar 21656,54466,722137,3330
01 Jan 21671,24664,281139,7330
30 Sep 20687,197125,663157,3780
30 Jun 20730,070115,905164,6290
31 Mar 20766,30395,441173,8250
01 Jan 20752,01486,364174,4070
30 Sep 19768,0827,658178,9430
30 Jun 19776,542-734182,0910
31 Mar 19786,3293,305191,8950
31 Dec 18804,18012,335197,6080
30 Sep 18781,39122,524195,3770
30 Jun 18778,21940,199181,6560
31 Mar 18799,90664,378169,8350
31 Dec 17765,34271,915161,9420
30 Sep 17760,22589,604136,1640
30 Jun 17750,78287,895145,6290
31 Mar 17713,78082,365139,4250
31 Dec 16737,80688,149132,4000
30 Sep 16719,32976,366138,4900
30 Jun 16707,00472,878132,6720
31 Mar 16704,04169,398126,7810
31 Dec 15669,56561,620117,0340
30 Sep 15680,33035,781143,6300
30 Jun 15676,77636,443145,4000
31 Mar 15679,59030,744160,7670
01 Jan 15709,56529,700178,4740
30 Sep 14697,08737,234165,8560
30 Jun 14701,72635,372159,4010
31 Mar 14699,49337,946146,3180

Quality Earnings: DCL has high quality earnings.

Growing Profit Margin: DCL's current net profit margins (5.4%) are lower than last year (6.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DCL's earnings have declined by 0.4% per year over the past 5 years.

Accelerating Growth: DCL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DCL had negative earnings growth (-16%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).

Return on Equity

High ROE: DCL's Return on Equity (4.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:41
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cuu Long Pharmaceutical Joint Stock Company is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Phuong HoangSSI Securities Corporation